Each dose of CABLIVI matters1
This dosing regimen may result in the established efficacy and safety profile of CABLIVI1
Discontinue CABLIVI if the patient experiences >2 recurrences of aTTP/iTTP‡ while on CABLIVI.
Withhold CABLIVI treatment 7 days prior to elective surgery, dental procedures, or other invasive interventions.
Avoid concomitant use of antiplatelet agents or anticoagulants.
*Must be administered at least 15 minutes prior to PEX.
†Administration can be continued for up to 28 additional days if signs of underlying disease persist, such as suppressed ADAMTS13 levels.
‡aTTP is also known as iTTP. The terms can be used interchangeably.
CHOOSE CABLIVI ON DAY 1 IN COMBINATION WITH PEX AND IMMUNOSUPPRESSIVE THERAPY
Who should not start CABLIVI?
- CABLIVI is contraindicated in patients with a previous severe hypersensitivity to caplacizumab-yhdp or to any of its excipients
- Withhold CABLIVI treatment 7 days prior to elective surgery, dental procedures, or other invasive interventions
Reconstituting and administering CABLIVI1,28
For full reconstitution and administration instructions, please refer to the Instructions
The first dose of CABLIVI should be administered by a healthcare provider as a bolus intravenous injection. Administer subsequent doses subcutaneously in the abdomen.
Avoid injections around the navel. Do not administer consecutive injections in the same abdominal quadrant.
Patients or caregivers may inject CABLIVI subcutaneously after proper training on the preparation and administration of CABLIVI, including aseptic technique.
Administration training video
Use this video with your patients to help them better understand CABLIVI administration.
Keep watching for CABLIVI Important Safety Information at the end of this video. Talk to your doctor about any questions you have about CABLIVI. Be sure that you read, understand, and follow the Instructions for Use before you inject CABLIVI and each time you get a refill. There may be new information. Your healthcare provider should show you how to prepare and inject CABLIVI properly before your first injection. Talk to your healthcare provider if you have any questions.
When it's time for your injection, take CABLIVI out of the refrigerator. Never freeze your vials. If needed, CABLIVI may be stored at room temperature for up to 2 months. It may be helpful to write the date it was removed from the refrigerator in the space provided on the carton. Keep CABLIVI in the carton that it came in to protect it from light. For each injection, one carton of CABLIVI is needed.
Wash your hands with soap and water and place all components of the kit on a clean, flat surface. Check to make sure the carton contains all the items needed to prepare a dose of CABLIVI. Only use the supplies that are provided in the carton to prepare your prescribed dose. Do not reuse any of the supplies. Check the expiration date on the package and vial.
If the carton was stored in the refrigerator, allow the vial and the syringe to reach room temperature by holding in your hands for 10 seconds.
Remove the green plastic flip-off cap from the vial, and clean the rubber stopper using one of the alcohol pads. Allow to dry for a few seconds.
Take the packed vial adapter and remove the paper cover leaving the vial adapter in its packaging for now.
Place the adapter over the vial, while keeping the adapter in its plastic packaging.
Press down firmly until the adapter snaps into place, with the adapter spike pushing through the vial stopper.
Leave the adapter attached to the vial, still in its outer packaging.
Holding the syringe in one hand, break off the white cap by snapping at the perforation of the cap with your other hand. Then lay the syringe on a clean flat surface.
Remove the plastic packaging from the adapter by pressing the sides of the adapter packaging, and then lifting the packaging upwards. Be sure that the adapter does not detach from the vial. Hold the adapter with the attached vial. Place the tip of the syringe on the connector part of the vial adapter. Gently lock the syringe onto the vial by turning it clockwise until it cannot twist any further.
Place the vial upright on a flat surface. Slowly push the syringe plunger down until the syringe is empty.
Gently swirl the vial with connected syringe until the powder is dissolved. Allow the vial with connected syringe to stand on the flat surface for 2 minutes to allow the solution to completely dissolve.
Use the mixed CABLIVI solution immediately. The mixed CABLIVI solution can be stored for up to 4 hours in the refrigerator. Check the solution for particles, cloudiness, or clumps. All powder must be fully dissolved, and the solution must be clear. Use a new carton or call your healthcare provider if solution is not clear. Slowly press the syringe's plunger fully down. Turn the whole - vial, adapter and syringe - upside down. While keeping it vertical, slowly pull the plunger to transfer all the solution into the syringe.
Turn the whole - vial, adapter and syringe - right-side up and place on the flat surface. Detach the filled syringe from the adapter by gently turning the syringe counter-clockwise. Put the vial and the attached adapter into a sharps disposal container. Place the syringe on the clean flat surface.
Remove the needle from the package, and attach it to the syringe without
needle cap by turning clockwise until it cannot twist any further. Pull back
Use the second alcohol pad to clean the injection site on your abdomen. Avoid the 2-inch area around your belly button. Let your skin dry.
Carefully remove the needle protection cap from the needle. Hold the syringe at eye level with the needle pointing upwards to see if there are any air bubbles. Remove any air bubbles by tapping the side of the syringe with your finger until they rise towards the tip. Then, slowly push the plunger until a small amount of liquid drips out of the needle. Gently pinch the cleaned skin between your thumb and forefinger to make a fold. Hold the pinch during the entire injection. Insert the full length of the needle into the skin fold at a 45- to 90-degree angle and press the plunger down until all of the solution is gone. Pull out the needle at the same angle you inserted it.
Right after your injection, move the needle safety shield over the needle until it clicks into place. In case you are bleeding at the injection site, place a cotton ball over the skin right away. Press gently on the cotton ball until the bleeding has stopped.
Put the syringe, needle, and vial with adapter in a sharps disposal container right away after use. If you do not have an FDA-cleared sharps disposal container, you may use a household container that meets specific requirements according to your community guidelines.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Who should not take CABLIVI?
Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
What should I tell my healthcare team before starting CABLIVI?
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
What are the possible side effects of CABLIVI?
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
ADAMTS13=a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; aTTP=acquired thrombotic thrombocytopenic purpura; ISTH=International Society on Thrombosis and Haemostasis; iTTP=immune-mediated thrombotic thrombocytopenic purpura; IV=intravenous; PEX=plasma exchange; SC=subcutaneous.
INFORMATION AND INDICATIONS
IMPORTANT SAFETY INFORMATION
CABLIVI is contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of its excipients. Hypersensitivity reactions have included urticaria.
WARNINGS AND PRECAUTIONS:
- CABLIVI increases the risk of bleeding. In clinical studies, severe bleeding adverse reactions of epistaxis, gingival bleeding, upper gastrointestinal hemorrhage, and metrorrhagia were each reported in 1% of subjects. Overall, bleeding events occurred in approximately 58% of patients on CABLIVI versus 43% of patients on placebo.
- In the postmarketing setting cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI.
- The risk of bleeding is increased in patients with underlying coagulopathies (e.g. hemophilia, other coagulation factor deficiencies). It is also increased with concomitant use of CABLIVI with drugs affecting hemostasis and coagulation.
- Avoid concomitant use of CABLIVI with antiplatelet agents or anticoagulants. If clinically significant bleeding occurs, interrupt use of CABLIVI. Von Willebrand factor concentrate may be administered to rapidly correct hemostasis. If CABLIVI is restarted, monitor closely for signs of bleeding.
- Withhold CABLIVI for 7 days prior to elective surgery, dental procedures or other invasive interventions. If emergency surgery is needed, the use of von Willebrand factor concentrate may be considered to correct hemostasis. After the risk of surgical bleeding has resolved, and CABLIVI is resumed, monitor closely for signs of bleeding.
The most common adverse reactions (>15% of patients) were epistaxis (29%), headache (21%) and gingival bleeding (16%).
CONCOMITANT USE OF ANTICOAGULANTS OR ANTIPLATELET AGENTS:
Concomitant use of CABLIVI with any anticoagulant or antiplatelet agent may increase the risk of bleeding. Avoid concomitant use when possible. Assess and monitor closely for bleeding with concomitant use.
There are no available data on CABLIVI use in pregnant women to inform a drug associated risk of major birth defects and miscarriage.
- Fetal/neonatal adverse reactions: CABLIVI may increase the risk of bleeding in the fetus and neonate. Monitor neonates for bleeding.
- Maternal adverse reactions: All patients receiving CABLIVI, including pregnant women, are at risk for bleeding. Pregnant women receiving CABLIVI should be carefully monitored for evidence of excessive bleeding.
CABLIVI (caplacizumab-yhdp) is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.
References: 1. CABLIVI Prescribing Information: Genzyme Corporation. 2. Scully M, Cataland SR, Peyvandi F, et al; for the HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-346. 3. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2486-2495. doi:10.1111/jth.15006. 4. Grall M, Azoulay E, Galicier L, et al. Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre. Am J Hematol. 2017;92(4):381-387. 5. Scully M, Hunt BJ, Benjamin S, et al. On behalf of British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323-335. 6. Goel R, King KE, Takemoto CM, Ness PM, Tobian AAR. Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: national representative data from 2007 to 2012. Transfusion. 2016;56(6):1451-1458. 7. Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2017;15(7):1448-1452. 8. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836-2846. 9. Masias C, Wu H, McGookey M, Jay L, Cataland S, Yang S. No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: the experience from the Ohio State University Registry. Am J Hematol. 2018;93(3):E73-E75. doi:10.1002/ajh.25002. 10. Schieppati F, Russo L, Marchetti M, et al. Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: a multi-institutional study. Am J Hematol. 2020;95(8):953-959. doi:10.1002/ajh.25845. 11. Knoebl P, Cataland S, Peyvandi F, et al. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020;18(2):479-484. doi:10.1111/jth.14679. 12. Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2017;130(14):1684. doi:10.1182/blood-2017-08-803171. 13. Kremer Hovinga JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers. 2017;3:17020. doi:10.1038/nrdp.2017.20. 14. Holz J-B. The TITAN trial—assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfus Apher Sci. 2012;46(3):343-346. 15. Azoulay E, Bauer PR, Mariotte E, et al; Nine-i Investigators. Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Med. 2019;45(11):1518-1539. doi:10.1007/s00134-019-05736-5. 16. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-1511. doi:10.1182/blood-2009-09-243790. 17. Upreti H, Kasmani J, Dane K, et al. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood. 2019;134(13):1037-1045. doi:10.1182/blood.2019001056. 18. Cuker A, Cataland SR, Coppo P, et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021;137(14):1855-1861. doi:10.1182/blood.2020009150. 19. Vincent J-L, Castro P, Hunt BJ, et al. Thrombocytopenia in the ICU: disseminated intravascular coagulation and thrombotic microangiopathies—what intensivists need to know. Crit Care. 2018;22(1):158. 20. Chiasakul T, Cuker A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematology Am Soc Hematol Educ Program. 2018;2018(1):530-538. 21. Canpolat N. Hemolytic uremic syndrome. Turk Pediatri Ars. 2015;50(2):73-82. 22. Venugopal A. Disseminated intravascular coagulation. Indian J Anaesth. 2014;58(5):603-608. 23. Wada H, Matsumoto T, Suzuki K, et al. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J. 2018;16:14. 24. Cataland SR, Wu HM. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood. 2014;123(16):2478-2484. 25. Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, de Cordoba SR. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016;14 Suppl 11(11):2-15. 26. Supplement to: Scully M, Cataland SR, Peyvandi F, et al; for the HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-346. doi:10.1056/NEJMoa1806311. 27. Protocol for: Scully M, Cataland SR, Peyvandi F, et al; for the HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-346. doi:10.1056/NEJMoa1806311. 28. CABLIVI [instructions for use]. Cambridge, MA: Genzyme Corporation. 29. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496-2502. doi:10.1111/jth.15010 30. Centers for Medicare & Medicaid Services. ICD-10-CM/PCS MS-DRGv37 Definitions Manual: MDC 8 Diseases & Disorders of the Musculoskeletal System & Connective Tissue Disorders. https://www.cms.gov/icd10m/version37-fullcode-cms/fullcode_cms/P0213.html. Updated September 12, 2019. Accessed January 9, 2023. 31. Centers for Medicare & Medicaid Services. 2023 ICD-10-CM. https://www.cms.gov/files/zip/2023-code-tables-tabular-and-index.zip. Updated July 27, 2022. Accessed January 9, 2023. 32. Centers for Medicare & Medicaid Services. 2023 ICD-10-PCS. https://www.cms.gov/files/zip/2023-icd-10-pcs-code-tables-and-index.zip. Accessed January 9, 2023.